Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AFM32
Therapeutic Area: Oncology Product Name: AFM32
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Roivant Sciences
Deal Size: $2,060.0 million Upfront Cash: $60.0 million
Deal Type: Collaboration November 09, 2020
Details:
The collaboration grants Roivant a license to the preclinical molecule AFM32. The collaboration will also leverage Affimed’s proprietary Redirected Optimized Cell Killing (ROCK®) platform to generate ICE® molecules against targets not included in Affimed’s current pipeline.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MOR210,Undisclosed
Therapeutic Area: Oncology Product Name: TJ210
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: I-Mab Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
MOR210/TJ210 is a highly differentiated monoclonal antibody that is directed against complement factor C5a receptor 1 (C5aR1). The phase 1 clinical trial, designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
